Real‐World Effectiveness and Safety of Damoctocog Alfa Pegol in Severe and Nonsevere Patients With Hemophilia A From the Prospective, Multinational, Ongoing <scp>HEM</scp> ‐ <scp>POWR</scp> Study
This updated analysis further demonstrated the effectiveness, acceptable safety profile, and tolerability of damoctocog alfa pegol for previously treated patients with severe and nonsevere hemophilia A from adolescence to older age in a real-world setting.
Authors
- Giancarlo Castaman (ORCID: https://orcid.org/0000-0003-4973-1317)
- Mark T. Reding (ORCID: https://orcid.org/0000-0003-3319-2806)
- María Teresa Álvarez Román (ORCID: https://orcid.org/0000-0003-3296-4288)
- Tadashi Matsushita (ORCID: https://orcid.org/0000-0002-3646-3125)
- Maissaa Janbain (ORCID: https://orcid.org/0000-0002-4176-9110)
- Karina Meijer (ORCID: https://orcid.org/0000-0001-9447-0465)
- Kathrin Schmidt (ORCID: https://orcid.org/0009-0000-3738-6304)
- Johannes Oldenburg (ORCID: https://orcid.org/0000-0002-1585-4100)
Institutions
- University Medical Center Groningen (NL)
- University of Bonn (DE)
- University Hospital Bonn (DE)
- Tulane Medical Center (US)
- Hospital Universitario La Paz (ES)
- Nagoya University Hospital (JP)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- University of Minnesota Medical Center (US)
- Bayer (Germany) (DE)
Publication Details
- Journal
- European Journal Of Haematology
- Published
- 2025-10-22
- DOI
- https://doi.org/10.1111/ejh.70026
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00